All

Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
2 June 2025

Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, will present positive data from its Phase 1/2 clinical study with...

Read more
Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025
30 May 2025

Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces it will present new positive data from its ongoing...

Read more
MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease
18 March 2025

MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more
SeaWeed Concept raises 2 million euros to expand production of seaweed for human consumption
21 February 2025

SeaWeed Concept raises 2 million euros to expand production of seaweed for human consumption

SeaWeed Concept, start-up specializing in the use of lacto-fermented seaweed for human consumption, has just raised 2 million euros from the Paris-based Blue Forward Fund. This...

Read more
Anybuddy raises €2M with Seventure Partners’ Sport & Performance Capital fund and becomes the benchmark in racquet sports by accelerating its focus on padel.
6 February 2025

Anybuddy raises €2M with Seventure Partners’ Sport & Performance Capital fund and becomes the benchmark in racquet sports by accelerating its focus on padel.

Anybuddy, France's leading racquet sports booking platform, has announced a €2 million round of financing to support its expansion and enhance its service offering.
By...

Read the press release
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
21 January 2025

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more
Extending Insights to the Small Intestine: Cmbio™ Teams Up with Nimble Science
21 January 2025

Extending Insights to the Small Intestine: Cmbio™ Teams Up with Nimble Science

Cmbio™, a global leader in multi-omics science and digital biology, announces a strategic partnership with Nimble Science, to deliver first in class high-quality, multi-omic...

Read more
Cmbio® Acquires Eagle Genomics’ Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform.
10 January 2025

Cmbio® Acquires Eagle Genomics’ Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform.

Cmbio®, a global leader in multi-omics science and digital biology, is pleased to announce the purchase of the e[datascientist]™ software platform through an Asset Sale...

Read more
Starfish signs an agreement with BioAster to expand its understanding of anaerobic soil bacteria
10 December 2024

Starfish signs an agreement with BioAster to expand its understanding of anaerobic soil bacteria

Starfish Bioscience, a specialist in microbiome-based solutions for soil regeneration, has just signed a partnership agreement with BioAster. This collaboration will expand...

Read more